HUP0401718A2 - Biciklusos oxo-piridin- és oxo-pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények - Google Patents

Biciklusos oxo-piridin- és oxo-pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0401718A2
HUP0401718A2 HU0401718A HUP0401718A HUP0401718A2 HU P0401718 A2 HUP0401718 A2 HU P0401718A2 HU 0401718 A HU0401718 A HU 0401718A HU P0401718 A HUP0401718 A HU P0401718A HU P0401718 A2 HUP0401718 A2 HU P0401718A2
Authority
HU
Hungary
Prior art keywords
atom
group
optionally substituted
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0401718A
Other languages
English (en)
Inventor
Jeremy Martin Davis
Daniel Christopher Brookings
Barry John Langham
Original Assignee
Celltech R&D Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Limited filed Critical Celltech R&D Limited
Publication of HUP0401718A2 publication Critical patent/HUP0401718A2/hu
Publication of HUP0401718A3 publication Critical patent/HUP0401718A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)

Abstract

A találmány az (1a) és (1b) általános képletű vegyületekre és sóikra,szolvátjaikra, hidrátjaikra, valamint N-oxidjaikra vonatkozik ahol aképletben a szaggatott vonal jelentése egy adott esetben jelenlévőkötés, A jelentése -N= atom vagy-N(Rb)-, -C(Rb)= vagy-C(Rb)(Rc)csoport, Ra, Rb és Rc mindegyikének jelentése egymástól függetlenülhidrogénatom vagy adott esetben helyettesített 1-6 szénatomosalkilcsoport, X jelentése oxigénatom, kénatom vagy -NH- csoport vagyhelyettesített nitrogénatom, Y jelentése egymástól függetlenülnitrogénatom vagy CH csoport vagy helyettesített szénatom, n értéke 0vagy 1, Alk1 jelentése adott esetben helyettesített alifás vagyheteroalifás lánc, L1 jelentése kovalens kötés, vagy egy összekötőatom vagy csoport, Cy1 jelentése hidrogénatom vagy adott esetbenhelyettesített cikloalifás, policikloalifás, heterocikloalifás,poliheterocikloalifás, aromás vagy heteroaromás csoport, Ar jelentéseadott esetben helyettesített aromás vagy heteroaromás csoport. Atalálmány szerinti vegyületek a p38 kinázok által közelítettbetegségek vagy rendellenességek megelőzésére vagy kezelésére szolgálógyógyszerek előállításához használhatók. Ó
HU0401718A 2001-10-16 2002-10-16 Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them HUP0401718A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124848.3A GB0124848D0 (en) 2001-10-16 2001-10-16 Chemical compounds
PCT/GB2002/004680 WO2003033502A1 (en) 2001-10-16 2002-10-16 Bicyclic oxopyridine and oxopyrimidine derivatives

Publications (2)

Publication Number Publication Date
HUP0401718A2 true HUP0401718A2 (hu) 2004-12-28
HUP0401718A3 HUP0401718A3 (en) 2008-07-28

Family

ID=9923964

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401718A HUP0401718A3 (en) 2001-10-16 2002-10-16 Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them

Country Status (17)

Country Link
US (1) US7176215B2 (hu)
EP (1) EP1438313A1 (hu)
JP (1) JP2005505627A (hu)
KR (1) KR20040062565A (hu)
CN (1) CN1310921C (hu)
AU (1) AU2002336172B2 (hu)
CA (1) CA2462147A1 (hu)
EA (1) EA007957B1 (hu)
GB (1) GB0124848D0 (hu)
HU (1) HUP0401718A3 (hu)
IL (1) IL161384A0 (hu)
MX (1) MXPA04003450A (hu)
NO (1) NO20041975L (hu)
NZ (1) NZ532713A (hu)
PL (1) PL369867A1 (hu)
WO (1) WO2003033502A1 (hu)
ZA (1) ZA200402803B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US7125898B2 (en) * 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
GB0222743D0 (en) * 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EA010297B1 (ru) * 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
AU2004249498B2 (en) * 2003-06-20 2009-11-19 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
JP2007516163A (ja) * 2003-06-20 2007-06-21 セルテック アール アンド ディ リミテッド ３−アミノチエノピリドン誘導体の調製方法
AU2004285752A1 (en) * 2003-10-24 2005-05-12 Ucb Pharma S.A. Thieno-pyridinone derivatives as kinase inhibitors
ES2339670T3 (es) * 2003-12-23 2010-05-24 Novartis Ag Inhibidores heterociclicos biciclicos de la quinasa p-38.
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
EP1879899B1 (en) * 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP2426134A3 (en) * 2005-11-23 2012-07-04 Intermune, Inc. Method of modulating stress-activated protein kinase system
HUP0501168A3 (en) * 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
WO2007072094A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
GB0915892D0 (en) * 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
CA2791884C (en) 2010-03-01 2018-04-24 Novadrug, Llc Compositions and methods for treating viral diseases
CA2846348C (en) * 2011-08-24 2019-01-22 Novadrug, Llc Compositions comprising perhydropyrrolo[3,2-c]pyridines and methods for their use in treating viral diseases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US10906899B2 (en) 2016-05-10 2021-02-02 Georgia State University Research Foundation, Inc. Bicyclic fused pyrazole derivatives for the treatment of RSV
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561013B2 (en) 1982-03-30 1987-04-30 Gruppo Lepetit S.P.A. Isoxazole(5,4-beta)pyridines
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
CA2121148A1 (en) 1992-08-19 1994-03-03 Satoru Nakai Apoptosis regulator
JPH0776586A (ja) * 1993-07-16 1995-03-20 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
JPH0959276A (ja) 1995-08-11 1997-03-04 Kumiai Chem Ind Co Ltd 縮合ヘテロ環誘導体及び除草剤
AU4429799A (en) * 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
GB2350111A (en) * 1999-05-17 2000-11-22 Bayer Ag Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
AU1626001A (en) * 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AR030273A1 (es) * 2000-03-10 2003-08-20 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina

Also Published As

Publication number Publication date
AU2002336172B2 (en) 2007-09-13
GB0124848D0 (en) 2001-12-05
CN1310921C (zh) 2007-04-18
PL369867A1 (en) 2005-05-02
NO20041975L (no) 2005-07-16
EA200400550A1 (ru) 2004-10-28
HUP0401718A3 (en) 2008-07-28
WO2003033502A1 (en) 2003-04-24
CA2462147A1 (en) 2003-04-24
NO20041975D0 (no) 2004-05-13
US7176215B2 (en) 2007-02-13
EA007957B1 (ru) 2007-02-27
ZA200402803B (en) 2006-06-28
US20040254200A1 (en) 2004-12-16
EP1438313A1 (en) 2004-07-21
CN1604901A (zh) 2005-04-06
IL161384A0 (en) 2004-09-27
KR20040062565A (ko) 2004-07-07
NZ532713A (en) 2005-10-28
JP2005505627A (ja) 2005-02-24
MXPA04003450A (es) 2004-07-16

Similar Documents

Publication Publication Date Title
HUP0401718A2 (hu) Biciklusos oxo-piridin- és oxo-pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
NZ537740A (en) Arylamine substituted bicyclic heteroaromatic compounds as P38 kinase inhibitors
HUP0103137A2 (hu) Oxazolo-, tiazolo- és szelenazolo-[4,5-c]-kinolin-4-aminok és analógjaik, eljárás az előállításukra a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
HUP0204245A2 (hu) Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401339A2 (hu) Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300894A2 (hu) Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
HUP0400888A2 (hu) Helyettesített ciklohexán-1,4-diamin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301311A2 (hu) N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
HUP0301272A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
HUP0301458A2 (hu) Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
HUP0302925A2 (hu) Gyulladásgátló szerekként alkalmazható amino-szubsztituált tetraciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények
HUP0203739A2 (hu) A hatos-gyűrűn helyettesített biciklikus imidazo-3-il-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0401350A2 (hu) Terápiás hatású új imidazopiridin-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HK1115728A1 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
DE60318874D1 (en) Pyrazolderivate
HUP0303045A2 (hu) Pirimidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: UCB PHARMA S.A., BE

Free format text: FORMER OWNER(S): CELLTECH R&D LIMITED, GB

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished